AVLNAvalyn Pharma Inc.

HealthcareUSD
$36.98

The financials

Avalyn Pharma Inc. by the numbers

Avalyn Pharma Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$31M−$19Mn/a
Net income−$29M−$18Mn/a
Diluted EPS−$0.98−$63.24n/a

Biotechnology

The closest names by size in the same industry

Compare peers
COAG-3.6%
Hemab Therapeutics Holdings, Inc.
IMTX-4.9%
Immatics N.V.
JBIO-0.41%
Jade Biosciences, Inc.
SVRA+3.4%
Savara Inc.
MNKD+2.3%
MannKind Corporation
DMRA+2.6%
Damora Therapeutics, Inc.